Last reviewed · How we verify
gemigliptin and rosuvastatin
Gemigliptin and rosuvastatin combination is a fixed-dose therapy developed by LG Life Sciences for the management of type 2 diabetes and hypercholesterolemia. The combination has completed Phase 3 trials and is under evaluation for regulatory approval. Key studies include pharmacokinetic interactions and bioequivalence assessments.
At a glance
| Generic name | gemigliptin and rosuvastatin |
|---|---|
| Sponsor | LG Life Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gemigliptin and rosuvastatin CI brief — competitive landscape report
- gemigliptin and rosuvastatin updates RSS · CI watch RSS
- LG Life Sciences portfolio CI